Delivery of miRNA-Targeted Oligonucleotides in the Rat Striatum by Magnetofection with Neuromag^®

Area of Science:

• Neuroscience
• Molecular Biology
• Biotechnology

Background:

• MicroRNAs (miRNAs) are key regulators of gene expression, and their aberrant levels are implicated in neurodegenerative diseases like Parkinson's disease (PD).
• Targeted delivery of oligonucleotide-based therapeutics, such as miRNA inhibitors, into the central nervous system (CNS) is crucial for neuroprotection and disease modification.
• Developing efficient carriers for brain-targeted delivery is essential for advancing miRNA-based therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy of Neuromag®, a polymeric magnetic particle, as a carrier for delivering synthetic miRNA inhibitors into the rat central nervous system.
• To assess the biodistribution and cellular uptake of Neuromag®-complexed oligonucleotides in specific brain regions.
• To determine the functional impact of delivered miRNA inhibitors on target miRNA levels.

Main Methods:

• Stereotaxic surgery was used to inject Neuromag®-complexed miRNA inhibitors into the lateral ventricles of rats.
• Fluorescence microscopy with fluorescein isothiocyanate (FITC)-labeled oligonucleotides was employed to visualize delivery in astrocytes and neurons within the striatum and septum.
• Real-time quantitative polymerase chain reaction (RT-qPCR) was utilized to measure the levels of specific miRNAs (miR-134) post-treatment.

Main Results:

• Neuromag® demonstrated efficient delivery of oligonucleotides into neurons and astrocytes in the striatum and septum.
• The delivered miRNA inhibitors were functionally effective, leading to significant inhibition of target miRNAs.
• Specifically, Neuromag®-mediated delivery of miR-134 antimiR resulted in a 0.35-fold decrease in striatal miR-134 levels.

Conclusions:

• The polymeric magnetic particle Neuromag® serves as an efficient delivery system for functional miRNA inhibitors in brain regions adjacent to the lateral ventricles, particularly the striatum.
• Neuromag® holds significant potential as a component of miRNA-based, disease-modifying therapies for neurological disorders, including Parkinson's disease.
• Further preclinical investigations using animal models of Parkinson's disease are warranted to explore the therapeutic applications of this delivery system.